Curosurf (Poractant Alfa)

Curosurf (Poractant Alfa) is a natural surfactant used for respiratory support in premature infants. This medication helps improve lung function and reduce respiratory distress. Learn more about its uses and effects.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs do not produce enough surfactant, a substance that keeps the air sacs open. By administering Curosurf, healthcare providers aim to improve lung function and facilitate breathing. The medication is administered via endotracheal tube directly into the lungs.

Curosurf works by replacing the natural surfactant in the lungs, which helps to reduce surface tension and keep the air sacs open. This can lead to improved breathing and reduced need for mechanical ventilation. Common effects may include temporary changes in oxygen levels and respiratory function.

Curosurf should be administered by trained healthcare professionals in a controlled medical setting. It is important to monitor the infant closely for any adverse reactions. Always follow the guidelines provided by the manufacturer and healthcare provider.

Curosurf is generally used in a controlled medical environment, so interactions with other medications are less common. However, it is important to inform healthcare providers about any other treatments the infant is receiving to ensure safety.